Key Insights

Highlights

Treatment Research

12 treatments under study, led by Nanatinostat

Research Leaders

5 sponsors active, led by The Methodist Hospital Research Institute

Related Conditions

Often studied with 12 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

3Total
Phase 1 (2)
Phase 2 (1)

Trial Status

Recruiting2
Terminated1

Clinical Trials (3)

Showing 3 of 3 trials
NCT06741072Phase 1Recruiting

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

NCT04664179Phase 1Recruiting

EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma

NCT05011058Phase 2Terminated

An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas

Showing all 3 trials

Research Network

Common Treatments

  • Nanatinostat1
  • Biospecimen Collection1
  • Dose Level 2a 6 X 107 Cellsm21
  • Dose Level 2b 6 X 107 Cellsm21
  • Peptide Vaccine1

Active Sponsors

  • The Methodist Hospital Research Institute1
  • Viracta Therapeutics, Inc.1
  • Ohio State University Comprehensive Cancer Center1
  • Baylor College of Medicine1
  • National Cancer Institute (NCI)1

Top Investigators

Related Conditions

  • Ebvrelated Hodgkin Lymphoma2
  • Chronic Kidney Disease Stage 41
  • Ebv Related Ptcl Nos1
  • Epsteinbarr Viruspositive Ebv Relapsedrefractory Lymphomas1
  • Ebvpositive Dlbcl Nos1

Activity Timeline